Patterns and prognostic indicators of response to CML treatment in a multi-country medical record review study

International Journal of Hematology

Volumn 95, Issue 5, 2012, Pages 535-544

  Trask, Peter C ^a   Mitra, Debanjali ^b   Iyer, Shrividya ^a   Candrilli, Sean D ^b   Kaye, James A ^b  

^a PFIZER INC   (United States)

^b RTI HEALTH SOLUTIONS   (United States)

Author keywords

Chronic myeloid leukemia; Imatinib; Prognostic factors; Treatment patterns

Indexed keywords

DASATINIB; IMATINIB; NILOTINIB;

ADULT; ARTICLE; CHRONIC MYELOID LEUKEMIA; DEMOGRAPHY; DRUG CHOICE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PROGNOSIS; SCORING SYSTEM; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CYTOGENETIC ANALYSIS; FEMALE; FUSION PROTEINS, BCR-ABL; GERMANY; GREAT BRITAIN; HUMANS; JAPAN; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PHILADELPHIA CHROMOSOME; PIPERAZINES; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RETROSPECTIVE STUDIES; THIAZOLES; TREATMENT OUTCOME; UNITED STATES;

EID: 84862871976     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-012-1043-8     Document Type: Article

References (26)

1. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in "good-risk" chronic granulocyic leukemia. Blood. 1984;63:789-99. (Pubitemid 14141296)
2. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004. (Pubitemid 36302244)
3. Hochhaus A, O'Brien SG, Guilhot F, Drucker BJ, Branford S, Foroni L, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23:1054-61.
4. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531-41. (Pubitemid 43882349)
5. Mauro MJ, Baccarani M, Cervantes F, Lipton JH, Matloub Y, Sinha R et al. Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C). J Clin Oncol. 2008; 26(May 20 suppl) (Abstract No. 7009).
6. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354:2542-51. (Pubitemid 43882350)
7. Kantarjian H, Giles FG, Bhalla J, Pinilla R, Larson N, Gattermann O et al. Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib resistance or intolerance: Longer follow-up results of a phase 2 study. Haematologica. 2009;94(suppl 2):254 (Abstract No. 0627).
8. Sokal JE, Baccarani M, Russo D, Tura S. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol. 1988;25:49-61.
9. Deininger M. Milestones and monitoring in patients with CML treated with imatinib. Hematology. American Society of Hematology Education Program Book 2008; 419-26.
10. De Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention to treat analysis. J Clin Oncol. 2008;26:3358-63.
11. Foryciarz K, Sacha T, Florek I, Czekalska S, Zawada M, Skotnicki AB. Prognostic factors in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors-single center experience. ASH Annual Meeting Abstracts. Blood. 2009; 114(22) (Abstract No. 2210).
12. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst. 1998;90(11):850-8. (Pubitemid 28280552)
13. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40(5): 373-83. (Pubitemid 17055592)
14. CIA World Factbook. https://www.cia.gov/library/publications/the-world- factbook/geos/ja.html. Accessed 18 Aug 2011.
15. Baccarani M, Dreyling M; on behalf of the ESMO Guidelines Working Group. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(suppl5):v165-7.
16. NCCN Guidelines. Version 2.2012. Chronic myelogenous leukemia. http://www.nccn.org/professionals/physician-gls/pdf/cml.pdf. Accessed 24 Aug 2011.
17. Darkow T, Henk HJ, Thomas SK, Feng W, Baladi J-F, Goldberg GA, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs. Pharmacoeconomics. 2007;25:481-96.
18. Kantarjian H, O'Brien S, Jabbour E, Shan J, Ravandi F, Kadia T, et al. Impact of treatment endpoint definitions on perceived differences in long-term outcomes with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. J Clin Oncol. 2011;29: 3173-8.
19. Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011;118: 686-92.
20. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355: 2408-17. (Pubitemid 44903745)
21. Hsiao HH, Liu YC, Tsai HJ, Hsu JF, Yang WC, Chang CS, et al. Additional chromosome abnormalities in chronic myeloid leukemia. Kaohsiung J Med Sci. 2001;27(2):49-54.
22. Kantarjian HM, Jabbour E, Giles FJ, Bhalla, KN, Pinilla-Ibarz J, Larson RA, et al. Prognostic factors for progression-free survival in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib based on 24 month data. Blood. 2009;114 (Abstract No. 3298).
23. Bjorkholm M, Ohm L, Eloranta S, Derolf A, Hultcrantz M, Sjöberg J, et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol. 2011;29:1-7.
24. Gugliotta G, Castagnetti F, Palandri F, Breccia M, Intermesoli T, Capucci A, et al. Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. Blood. 2011;117:5591-9.
25. Wu EQ, Guerin A, Yu AP, Bollu VK, Guo A, Griffin JD. Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. Curr Med Res Opin. 2010;26:2861-9.
26. Mitra D, Trask PC, Iyer S, Candrilli SD, Kaye JA. Patient characteristics and treatment patterns in chronic myeloid leukemia: evidence from a multi-country retrospective medical record chart review study. Int J Hematol. 2012;95(3):263-273.